$0.8370
-0.057-6.38%
Last update: Nov 10, 3:12 AM
Nyxoah SA
NYXHNASDAQ
Nyxoah fell 83.4% from $5.37 to $0.89, behind the S&P 500's +10.5%. Its worst day was Jun 5 (−49.7%), and its low came Nov 5 at $0.81.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.74 missed the $-0.61 estimate on $2.3M revenue (est. $1.9M).
−5.8% · S&P 500 0.0%
EPS of $-0.68 missed the $-0.65 estimate on $6.6M revenue (est. $6.7M).
Story events cover the past 12 months · Times ET
−1.3% · S&P 500 −1.4%
EPS of $-0.43 beat the $-0.54 estimate on $7.5M revenue (est. $7.1M); FY revenue guidance of $42.2M–$46.8M against the $37.2M consensus.
+0.3% · S&P 500 +0.6%
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on developing innovative solutions for Obstructive Sleep Apnea (OSA), today announced the comm…
−49.7%, the year's worst day · S&P 500 −2.6%
EPS of $-0.67 missed the $-0.47 estimate on $8.9M revenue (est. $9.0M); FY revenue guidance of $41.9M–$46.5M against the $44.4M consensus.
−7.1% · S&P 500 −0.2%
Nyxoah shares rose 16.6%, while the S&P 500 rose 1.0%.
+16.6%, the year's best day, on 5M shares, the year's heaviest volume · S&P 500 +1.0%
Nyxoah shares rose 14.2%, while the S&P 500 rose 0.5%.
+14.2% · S&P 500 +0.5%
Third Quarter 2026 – Preliminary Sales and Market MetricsFinancialsGlobal net revenue is expected to be approximately €9.2 million in the third quarter of 2026, which reflects 19% sequential growth over the second
−14.0% · S&P 500 +0.4%
EPS of $-0.20 beat the $-0.24 estimate on $10.6M revenue (est. $11.1M); FY revenue guidance of $38.0M–$40.3M against the $43.3M consensus.
+4.3% · S&P 500 +0.3%
Where it ended: a close of $0.89 on Nov 9, 2026.
Nothing in the past 12 months.
All NYXH dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for NYXH and SPY from Benzinga historical bars. Not investment advice.
